FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccine / Impact of immunization against SpyCEP during invasive diseas...
Vaccine2009; 27(36); 4923-4929; doi: 10.1016/j.vaccine.2009.06.042

Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi.

Abstract: Currently there is no licensed vaccine against the human pathogen Streptococcus pyogenes. The highly conserved IL-8 cleaving S. pyogenes cell envelope proteinase SpyCEP is surface expressed and is a potential vaccine candidate. A recombinant N-terminal part of SpyCEP (CEP) was expressed and purified. AntiCEP antibodies were found to neutralize the IL-8 cleaving activity of SpyCEP. CEP-immunized mice had reduced bacterial dissemination from focal S. pyogenes intramuscular infection and intranasal infection. We also identified a functional SpyCEP-homolog protease SeCEP, expressed by the equine pathogen Streptococcus equi, which was able to cleave both human and equine IL-8. CEP-immunized mice also demonstrated reduced bacterial dissemination from S. equi intramuscular infection. Therefore immunization against SpyCEP may provide protection against other streptococci species with homologous proteases.
Get Full Text
Publication Date: 2009-06-27 PubMed ID: 19563892PubMed Central: PMC2759039DOI: 10.1016/j.vaccine.2009.06.042Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article explores the potential of using immunization against SpyCEP, a proteinase found in Streptococcus pyogenes, to protect against infection. The study found that antiCEP antibodies neutralized the IL-8 cleaving activity of SpyCEP, which reduced bacterial spread in mice. Interestingly, the findings also suggest that immunization against SpyCEP could potentially offer protection against other streptococcal species with similar proteases.

Introduction to the Research

  • At the present, there is no licensed vaccine against Streptococcus pyogenes, a harmful human pathogen.
  • This study investigated the potential of using a conserved proteinase called SpyCEP, found on the cell surface of S. pyogenes, as a vaccine candidate.

Study Methodology

  • The researchers created a recombinant, or genetically engineered, N-terminal part of SpyCEP, referred to as CEP.
  • They then purified this CEP for use in their study.

Results and Findings

  • It was found that antibodies against CEP (known as antiCEP antibodies) effectively neutralized the function of SpyCEP that cleaves IL-8, a protein responsible for attracting neutrophils, a type of white blood cell involved in fighting infections.
  • This neutralization activity thus limited the ability of the bacteria to spread within the host.
  • In mice, it was observed that immunization with CEP led to a reduction in bacterial dissemination from a local S. pyogenes infection, both when the bacterium was introduced via an intramuscular route and through an intranasal route.

Additional Findings

  • The researchers also identified a SpyCEP-equivalent, SeCEP, in Streptococcus equi, a pathogen commonly found in horses.
  • SeCEP was also found to cleave both human and equine IL-8.
  • Interestingly, mice immunized with CEP showed a reduced spread of S. equi infection as well.

Implications of the Research

  • These results suggest that immunizing against SpyCEP may have the broader potential of providing protection against other species of streptococci that express similar proteases.
  • The exploration of SpyCEP as a potential vaccine candidate holds promise in future immunization strategies against S. pyogenes and possibly a range of other streptococci bacteria.

Cite This Article

APA
Turner CE, Kurupati P, Wiles S, Edwards RJ, Sriskandan S. (2009). Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi. Vaccine, 27(36), 4923-4929. https://doi.org/10.1016/j.vaccine.2009.06.042

Publication

Vaccine
ISSN: 1873-2518
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 27
Issue: 36
Pages: 4923-4929

Researcher Affiliations

Turner, Claire E
  • Department of Infectious Diseases & Immunity, Hammersmith Hospital, Du Cane Road, London, W12 0NN, United Kingdom.
Kurupati, Prathiba
    Wiles, Siouxsie
      Edwards, Robert J
        Sriskandan, Shiranee

          MeSH Terms

          • Amino Acid Sequence
          • Animals
          • Antibodies, Bacterial / immunology
          • Antigens, Bacterial / immunology
          • Colony Count, Microbial
          • Liver / microbiology
          • Mice
          • Molecular Sequence Data
          • Neutralization Tests
          • Peptide Hydrolases / immunology
          • Sequence Alignment
          • Spleen / microbiology
          • Streptococcal Infections / prevention & control
          • Streptococcal Infections / therapy
          • Streptococcal Vaccines / immunology
          • Streptococcus equi / immunology
          • Streptococcus pyogenes / immunology
          • Vaccines, Synthetic / immunology

          Grant Funding

          • BB/E52708X/1 / Biotechnology and Biological Sciences Research Council
          • G0800777 / Medical Research Council
          • Wellcome Trust

          References

          This article includes 21 references
          1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases.. Lancet Infect Dis 2005 Nov;5(11):685-94.
            pubmed: 16253886doi: 10.1016/S1473-3099(05)70267-Xgoogle scholar: lookup
          2. Cunningham MW. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease.. Front Biosci 2003 May 1;8:s533-43.
            pubmed: 12700052doi: 10.2741/1067google scholar: lookup
          3. Dale JB, Beachey EH. Multiple, heart-cross-reactive epitopes of streptococcal M proteins.. J Exp Med 1985 Jan 1;161(1):113-22.
            pmc: PMC2187556pubmed: 2578539doi: 10.1084/jem.161.1.113google scholar: lookup
          4. Fischetti VA, Bessen DE, Schneewind O, Hruby DE. Protection against streptococcal pharyngeal colonization with vaccines composed of M protein conserved regions.. Adv Exp Med Biol 1991;303:159-67.
            pubmed: 1805563doi: 10.1007/978-1-4684-6000-1_17google scholar: lookup
          5. Olive C, Clair T, Yarwood P, Good MF. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.. Vaccine 2002 Jun 21;20(21-22):2816-25.
            pubmed: 12034109doi: 10.1016/s0264-410x(02)00205-0google scholar: lookup
          6. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers.. Clin Infect Dis 2005 Oct 15;41(8):1114-22.
            pubmed: 16163629doi: 10.1086/444458google scholar: lookup
          7. Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes.. Clin Diagn Lab Immunol 2005 Jul;12(7):833-6.
            pmc: PMC1182208pubmed: 16002631doi: 10.1128/CDLI.12.7.833-836.2005google scholar: lookup
          8. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.. JAMA 2004 Aug 11;292(6):709-15.
            pubmed: 15304468doi: 10.1001/jama.292.6.709google scholar: lookup
          9. Cole JN, Henningham A, Gillen CM, Ramachandran V, Walker MJ. Human pathogenic streptococcal proteomics and vaccine development.. Proteomics Clin Appl 2008 Mar;2(3):387-410.
            pubmed: 21136841doi: 10.1002/prca.200780048google scholar: lookup
          10. Rodríguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, Scarselli M, Doro F, Ferrari G, Garaguso I, Maggi T, Neumann A, Covre A, Telford JL, Grandi G. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome.. Nat Biotechnol 2006 Feb;24(2):191-7.
            pubmed: 16415855doi: 10.1038/nbt1179google scholar: lookup
          11. Edwards RJ, Taylor GW, Ferguson M, Murray S, Rendell N, Wrigley A, Bai Z, Boyle J, Finney SJ, Jones A, Russell HH, Turner C, Cohen J, Faulkner L, Sriskandan S. Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes.. J Infect Dis 2005 Sep 1;192(5):783-90.
            pubmed: 16088827doi: 10.1086/432485google scholar: lookup
          12. Waller AS, Jolley KA. Getting a grip on strangles: recent progress towards improved diagnostics and vaccines.. Vet J 2007 May;173(3):492-501.
            pubmed: 16820310doi: 10.1016/j.tvjl.2006.05.011google scholar: lookup
          13. Zinkernagel AS, Timmer AM, Pence MA, Locke JB, Buchanan JT, Turner CE, Mishalian I, Sriskandan S, Hanski E, Nizet V. The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing.. Cell Host Microbe 2008 Aug 14;4(2):170-8.
            pmc: PMC2631432pubmed: 18692776doi: 10.1016/j.chom.2008.07.002google scholar: lookup
          14. Biswas I, Germon P, McDade K, Scott JR. Generation and surface localization of intact M protein in Streptococcus pyogenes are dependent on sagA.. Infect Immun 2001 Nov;69(11):7029-38.
            pmc: PMC100083pubmed: 11598078doi: 10.1128/IAI.69.11.7029-7038.2001google scholar: lookup
          15. Sumby P, Zhang S, Whitney AR, Falugi F, Grandi G, Graviss EA, Deleo FR, Musser JM. A chemokine-degrading extracellular protease made by group A Streptococcus alters pathogenesis by enhancing evasion of the innate immune response.. Infect Immun 2008 Mar;76(3):978-85.
            pmc: PMC2258835pubmed: 18174342doi: 10.1128/IAI.01354-07google scholar: lookup
          16. Turner CE, Kurupati P, Jones MD, Edwards RJ, Sriskandan S. Emerging role of the interleukin-8 cleaving enzyme SpyCEP in clinical Streptococcus pyogenes infection.. J Infect Dis 2009 Aug 15;200(4):555-63.
            pmc: PMC2820315pubmed: 19591574doi: 10.1086/603541google scholar: lookup
          17. Hidalgo-Grass C, Mishalian I, Dan-Goor M, Belotserkovsky I, Eran Y, Nizet V, Peled A, Hanski E. A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues.. EMBO J 2006 Oct 4;25(19):4628-37.
            pmc: PMC1589981pubmed: 16977314doi: 10.1038/sj.emboj.7601327google scholar: lookup
          18. Sjölinder H, Lövkvist L, Plant L, Eriksson J, Aro H, Jones A, Jonsson AB. The ScpC protease of Streptococcus pyogenes affects the outcome of sepsis in a murine model.. Infect Immun 2008 Sep;76(9):3959-66.
            pmc: PMC2519448pubmed: 18573900doi: 10.1128/IAI.00128-08google scholar: lookup
          19. Fischetti VA. Streptococcal M protein: molecular design and biological behavior.. Clin Microbiol Rev 1989 Jul;2(3):285-314.
            pmc: PMC358122pubmed: 2670192doi: 10.1128/CMR.2.3.285google scholar: lookup
          20. Timoney JF. The pathogenic equine streptococci.. Vet Res 2004 Jul-Aug;35(4):397-409.
            pubmed: 15236673doi: 10.1051/vetres:2004025google scholar: lookup
          21. Beres SB, Sesso R, Pinto SW, Hoe NP, Porcella SF, Deleo FR, Musser JM. Genome sequence of a Lancefield group C Streptococcus zooepidemicus strain causing epidemic nephritis: new information about an old disease.. PLoS One 2008 Aug 21;3(8):e3026.
            pmc: PMC2516327pubmed: 18716664doi: 10.1371/journal.pone.0003026google scholar: lookup

          Citations

          This article has been cited 27 times.
          1. Iyer V, Sagar V, Toor D, Lyngdoh V, Nongrum G, Kapoor M, Chakraborti A. Group A Streptococcus Infections: Their Mechanisms, Epidemiology, and Current Scope of Vaccines.. Cureus 2022 Dec;14(12):e33146.
            doi: 10.7759/cureus.33146pubmed: 36721580google scholar: lookup
          2. McKenna S, Huse KK, Giblin S, Pearson M, Majid Al Shibar MS, Sriskandan S, Matthews S, Pease JE. The Role of Streptococcal Cell-Envelope Proteases in Bacterial Evasion of the Innate Immune System.. J Innate Immun 2022;14(2):69-88.
            doi: 10.1159/000516956pubmed: 34649250google scholar: lookup
          3. Shaw HA, Ozanne J, Burns K, Mawas F. Multicomponent Vaccines against Group A Streptococcus Can Effectively Target Broad Disease Presentations.. Vaccines (Basel) 2021 Sep 15;9(9).
            doi: 10.3390/vaccines9091025pubmed: 34579262google scholar: lookup
          4. Castro SA, Dorfmueller HC. A brief review on Group A Streptococcus pathogenesis and vaccine development.. R Soc Open Sci 2021 Mar 10;8(3):201991.
            doi: 10.1098/rsos.201991pubmed: 33959354google scholar: lookup
          5. Reynolds S, Pandey M, Dooley J, Calcutt A, Batzloff M, Ozberk V, Mills JL, Good M. Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines.. Sci Rep 2021 Jan 8;11(1):127.
            doi: 10.1038/s41598-020-80508-6pubmed: 33420258google scholar: lookup
          6. McKenna S, Malito E, Rouse SL, Abate F, Bensi G, Chiarot E, Micoli F, Mancini F, Gomes Moriel D, Grandi G, Mossakowska D, Pearson M, Xu Y, Pease J, Sriskandan S, Margarit I, Bottomley MJ, Matthews S. Structure, dynamics and immunogenicity of a catalytically inactive CXC chemokine-degrading protease SpyCEP from Streptococcus pyogenes.. Comput Struct Biotechnol J 2020;18:650-660.
            doi: 10.1016/j.csbj.2020.03.004pubmed: 32257048google scholar: lookup
          7. Bi S, Xu M, Zhou Y, Xing X, Shen A, Wang B. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.. mBio 2019 Nov 26;10(6).
            doi: 10.1128/mBio.02600-19pubmed: 31772056google scholar: lookup
          8. Azuar A, Jin W, Mukaida S, Hussein WM, Toth I, Skwarczynski M. Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems Against Group A Streptococcus.. Vaccines (Basel) 2019 Jul 1;7(3).
            doi: 10.3390/vaccines7030058pubmed: 31266253google scholar: lookup
          9. Goldblatt J, Lawrenson RA, Muir L, Dattani S, Hoffland A, Tsuchiya T, Kanegasaki S, Sriskandan S, Pease JE. A Requirement for Neutrophil Glycosaminoglycans in Chemokine:Receptor Interactions Is Revealed by the Streptococcal Protease SpyCEP.. J Immunol 2019 Jun 1;202(11):3246-3255.
            doi: 10.4049/jimmunol.1801688pubmed: 31010851google scholar: lookup
          10. Ozberk V, Pandey M, Good MF. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.. Hum Vaccin Immunother 2018;14(8):2034-2052.
            doi: 10.1080/21645515.2018.1462427pubmed: 29873591google scholar: lookup
          11. Gandhi GD, Krishnamoorthy N, Motal UMA, Yacoub M. Towards developing a vaccine for rheumatic heart disease.. Glob Cardiol Sci Pract 2017 Mar 31;2017(1):e201704.
            doi: 10.21542/gcsp.2017.4pubmed: 28971103google scholar: lookup
          12. Pandey M, Ozberk V, Calcutt A, Langshaw E, Powell J, Rivera-Hernandez T, Ho MF, Philips Z, Batzloff MR, Good MF. Streptococcal Immunity Is Constrained by Lack of Immunological Memory following a Single Episode of Pyoderma.. PLoS Pathog 2016 Dec;12(12):e1006122.
            doi: 10.1371/journal.ppat.1006122pubmed: 28027314google scholar: lookup
          13. Zaman M, Ozberk V, Langshaw EL, McPhun V, Powell JL, Phillips ZN, Ho MF, Calcutt A, Batzloff MR, Toth I, Hill GR, Pandey M, Good MF. Novel platform technology for modular mucosal vaccine that protects against streptococcus.. Sci Rep 2016 Dec 15;6:39274.
            doi: 10.1038/srep39274pubmed: 27976706google scholar: lookup
          14. DebRoy S, Saldaña M, Travisany D, Montano A, Galloway-Peña J, Horstmann N, Yao H, González M, Maass A, Latorre M, Shelburne SA. A Multi-Serotype Approach Clarifies the Catabolite Control Protein A Regulon in the Major Human Pathogen Group A Streptococcus.. Sci Rep 2016 Sep 1;6:32442.
            doi: 10.1038/srep32442pubmed: 27580596google scholar: lookup
          15. Rivera-Hernandez T, Pandey M, Henningham A, Cole J, Choudhury B, Cork AJ, Gillen CM, Ghaffar KA, West NP, Silvestri G, Good MF, Moyle PM, Toth I, Nizet V, Batzloff MR, Walker MJ. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.. mBio 2016 Jun 14;7(3).
            doi: 10.1128/mBio.00618-16pubmed: 27302756google scholar: lookup
          16. Reglinski M, Lynskey NN, Choi YJ, Edwards RJ, Sriskandan S. Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG.. J Infect 2016 Apr;72(4):450-9.
            doi: 10.1016/j.jinf.2016.02.002pubmed: 26880087google scholar: lookup
          17. Walker MJ, Barnett TC, McArthur JD, Cole JN, Gillen CM, Henningham A, Sriprakash KS, Sanderson-Smith ML, Nizet V. Disease manifestations and pathogenic mechanisms of Group A Streptococcus.. Clin Microbiol Rev 2014 Apr;27(2):264-301.
            doi: 10.1128/CMR.00101-13pubmed: 24696436google scholar: lookup
          18. Kuhn ML, Prachi P, Minasov G, Shuvalova L, Ruan J, Dubrovska I, Winsor J, Giraldi M, Biagini M, Liberatori S, Savino S, Bagnoli F, Anderson WF, Grandi G. Structure and protective efficacy of the Staphylococcus aureus autocleaving protease EpiP.. FASEB J 2014 Apr;28(4):1780-93.
            doi: 10.1096/fj.13-241737pubmed: 24421400google scholar: lookup
          19. Alam FM, Bateman C, Turner CE, Wiles S, Sriskandan S. Non-invasive monitoring of Streptococcus pyogenes vaccine efficacy using biophotonic imaging.. PLoS One 2013;8(11):e82123.
            doi: 10.1371/journal.pone.0082123pubmed: 24278474google scholar: lookup
          20. Henningham A, Ericsson DJ, Langer K, Casey LW, Jovcevski B, Chhatwal GS, Aquilina JA, Batzloff MR, Kobe B, Walker MJ. Structure-informed design of an enzymatically inactive vaccine component for group A Streptococcus.. mBio 2013 Aug 6;4(4).
            doi: 10.1128/mBio.00509-13pubmed: 23919999google scholar: lookup
          21. Chiappini N, Seubert A, Telford JL, Grandi G, Serruto D, Margarit I, Janulczyk R. Streptococcus pyogenes SpyCEP influences host-pathogen interactions during infection in a murine air pouch model.. PLoS One 2012;7(7):e40411.
            doi: 10.1371/journal.pone.0040411pubmed: 22848376google scholar: lookup
          22. Liu M, Zhu H, Li J, Garcia CC, Feng W, Kirpotina LN, Hilmer J, Tavares LP, Layton AW, Quinn MT, Bothner B, Teixeira MM, Lei B. Group A Streptococcus secreted esterase hydrolyzes platelet-activating factor to impede neutrophil recruitment and facilitate innate immune evasion.. PLoS Pathog 2012;8(4):e1002624.
            doi: 10.1371/journal.ppat.1002624pubmed: 22496650google scholar: lookup
          23. Cole JN, Barnett TC, Nizet V, Walker MJ. Molecular insight into invasive group A streptococcal disease.. Nat Rev Microbiol 2011 Sep 16;9(10):724-36.
            doi: 10.1038/nrmicro2648pubmed: 21921933google scholar: lookup
          24. Bugrysheva J, Froehlich BJ, Freiberg JA, Scott JR. Serine/threonine protein kinase Stk is required for virulence, stress response, and penicillin tolerance in Streptococcus pyogenes.. Infect Immun 2011 Oct;79(10):4201-9.
            doi: 10.1128/IAI.05360-11pubmed: 21788381google scholar: lookup
          25. Huang YS, Fisher M, Nasrawi Z, Eichenbaum Z. Defense from the Group A Streptococcus by active and passive vaccination with the streptococcal hemoprotein receptor.. J Infect Dis 2011 Jun 1;203(11):1595-601.
            doi: 10.1093/infdis/jir149pubmed: 21592989google scholar: lookup
          26. Shelburne SA, Olsen RJ, Suber B, Sahasrabhojane P, Sumby P, Brennan RG, Musser JM. A combination of independent transcriptional regulators shapes bacterial virulence gene expression during infection.. PLoS Pathog 2010 Mar 19;6(3):e1000817.
            doi: 10.1371/journal.ppat.1000817pubmed: 20333240google scholar: lookup
          27. Kurupati P, Turner CE, Tziona I, Lawrenson RA, Alam FM, Nohadani M, Stamp GW, Zinkernagel AS, Nizet V, Edwards RJ, Sriskandan S. Chemokine-cleaving Streptococcus pyogenes protease SpyCEP is necessary and sufficient for bacterial dissemination within soft tissues and the respiratory tract.. Mol Microbiol 2010 Jun;76(6):1387-97.
            doi: 10.1111/j.1365-2958.2010.07065.xpubmed: 20158613google scholar: lookup
          Subscribe to our newsletter
          Join 99,359 horse owners like you who receive our email updates on horse health and nutrition.